Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Safety and efficacy of durvalumab with R-CHOP or R ² -CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial.

Autor: Nowakowski GS; Division of Hematology, Mayo Clinic Rochester, 200 1st St SW, Rochester, MN, 55902, USA. nowakowski.grzegorz@mayo.edu., Willenbacher W; Internal Medicine, Hematology and Oncology Department, Innsbruck Medical University, Innsbruck, Austria.; Oncotyrol, Center for Personalized Cancer Medicine, Innsbruck, Austria., Greil R; Salzburg Cancer Research Institute and Cancer Cluster, Paracelsus Medical University Salzburg, Salzburg, Austria., Larsen TS; Department of Hematology, Odense University Hospital, Odense, Denmark., Patel K; Swedish Cancer Institute Hematology and Oncology Department, Center for Blood Disorders and Stem Cell Transplantation, Seattle, WA, USA., Jäger U; Division of Hematology and Hemostseology, Medical University of Vienna, Vienna, Austria., Manges RF; Parkview Health, Parkview Cancer Institute, Hematology Tumor Site, Fort Wayne, IN, USA., Trümper L; Department of Hematology-Oncology, Universitätsmedizin Göttingen, Göttingen, Germany., Everaus H; Haematology and Oncology Clinic, Tartu University Hospital, Tartu, Estonia., Kalakonda N; University of Liverpool and The Clatterbridge Cancer Centre, Liverpool, UK., Brown P; Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Jørgensen JM; Aarhus University Hospital, Aarhus, Denmark., Cunningham D; The Royal Marsden Hospital, The Institute of Cancer Research, Sutton, Surrey, UK., Dell'Aringa J; Celgene International, Boudry, Switzerland., Fox B; Celgene International, Boudry, Switzerland., Rubio ND; Celgene International, Boudry, Switzerland., Kilavuz N; Celgene International, Boudry, Switzerland., Casadebaig ML; Celgene International, Boudry, Switzerland., Manzke O; Celgene International, Boudry, Switzerland., Munoz J; Banner MD Anderson Cancer Center, Phoenix, AZ, USA.

Publikováno v: International journal of hematology [Int J Hematol] 2022 Feb; Vol. 115 (2), pp. 222-232. Date of Electronic Publication: 2021 Nov 19.